Loading
Loading
Tissue Repair & Recovery · 25mg + 10mg + 10mg
Janoshik-tested · 10 vials per kit
Coremend is a research blend of TB-500, BPC-157, and KPV studied in preclinical research for synergistic soft tissue repair. TB-500 supports cytoskeletal rebuilding and vascular network restoration; BPC-157 provides chemotactic signals and matrix template support; KPV modulates inflammatory feedback. Research has examined their combined potential to accelerate and improve the quality of soft tissue and mucosal healing while reducing fibrosis and maintaining immune homeostasis.
Blended compound — purity note
Peptide blends are not tested for combined purity as a single compound. However, every component is sourced from the same supplier as our individual peptide products, all of which carry valid Janoshik Analytical COAs. Those certificates apply equally to the same peptides in this blend. View individual COAs →
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
TB-500
Thymosin Beta-4 Fragment
TB-500 is a synthetic peptide derived from the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide expressed in virtually all nucleated human cells. Tβ4 was first isolated from thymus tissue in 1966 and is among the most abundant intracellular peptides in the body. Research into TB-500 focuses on the key LKKTETQ actin-binding motif responsible for most of the biological activity observed in Tβ4 studies.
The primary mechanism is G-actin sequestration: TB-500 binds monomeric (G-) actin, regulating the actin polymerisation-depolymerisation equilibrium critical for cell motility and migration. It also promotes angiogenesis through upregulation of VEGF, KGF, and HGF, and reduces expression of inflammatory cytokines including TNF-α and IL-8. Interaction with integrin-linked kinase (ILK) at the cell surface further contributes to its role in promoting survival and differentiation.
TB-500 has been studied in preclinical models of wound healing, cardiac repair (myocardial infarction models), tendon injury, dry eye syndrome, and hair follicle activation. It is frequently studied in combination with BPC-157, where the two peptides appear to have complementary rather than overlapping mechanisms. Research also suggests Tβ4 may reduce fibrosis formation during the healing process.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
